TWTianjiao Wang

Tianjiao Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tianjiao Wang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Liang

    Bioinformatics of Department, Key laboratory of Cell Biology, School of Life Sciences, China Medical University, Shenyang, China

    2 shared publications
  • Fang Xie

    Medical Basic Experimental Teaching Center, China Medical University, Shenyang, China

    1 shared publication
  • Junjie Huang

    Department of Bioinformatics, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, Shenyang 110122, China

    1 shared publication
  • Yunhui Li

    Department of Vascular Surgery, Jinan People's Hospital Affiliated to Shandong First Medical University, China

    1 shared publication

Latest Publications

  • Downregulation of ACE2 is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma

    by Tianjiao Wang, Fang Xie, Yun-Hui Li, Bin Liang

    Aims: The aim of this study was to explore the alteration in ACE2 expression and correlation between ACE2 expression and immune infiltration in clear cell renal cell carcinoma (ccRCC). Methods: The... Lay abstract To date, the morbidity and mortality of clear cell renal cell carcinoma (ccRCC) are gradually increasing, and ccRCC is more aggressive than other kidney cancer types. The ACE2 protein ...


  • Open Access

    FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis

    by Junjie Huang, Bin Liang, Tianjiao Wang

    Forkhead box D1 (FOXD1) is a new member of FOX transcription factor family. FOXD1 has demonstrated multilevel roles during normal development, and several diseases’ pathogenesis. However, little is known about the role of FOXD1 in the progression of head and neck squamous cancer (HNSC). In the present study, we analyzed FOXD1 expression pattern using The Cancer Genome Atlas (TCGA) dataset, Gene Expression Omnibus (GEO) datasets, HNSC cell lines, and HNSC tissues. Then, we analyzed the correlation between FOXD1 expression and clinical characteristics, and evaluated the prognostic value of FOXD1 in HNSC. Moreover, we assessed the relationship between FOXD1 expression and tumor microenvironment (TME) and immune cell infiltration using Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) and Cell-type Identification By Estimating Relative Subsets Of known RNA Transcripts (CIBERSORT) algorithms. Finally, we predicted the FOXD1-related biological processes (BPs) and signal pathways. FOXD1 was up-regulated in HNSC tissues in TCGA datasets, validated by GEO datasets, HNSC cell lines and HNSC tissues. FOXD1 expression was significantly associated with tumor site and HPV infection. Univariate and multivariate Cox regression analyses showed that FOXD1 expression was an independent prognostic factor. Moreover, we found that the proportions of naïve B cells, plasma cells, and resting dendritic cells (DCs) were negatively correlated with FOXD1 expression, otherwise, the proportion of activated mast cells was positively correlated with FOXD1 expression using CIBERSORT algorithm. Gene Set Enrichment Analyses (GSEAs) revealed that FOXD1 was mainly involved in cancer-related signaling pathway and metabolism-related pathways. FOXD1 was a potential oncogene, and might represent an indicator for predicting overall survival (OS) of HNSC patients. Moreover, many cancer-related pathways and metabolism-related processes may be regulated by FOXD1.